FBN1 and COVID-19: Since COVID-19 disproportionately affects patients with these comorbidities—conditions in which asprosin is already dysregulated—its modulation of glucose metabolism, appetite, and inflammatory signaling [20] may represent a key link between metabolic dysfunction and the hyperinflammatory state observed in COVID-19.